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Abstract
Rationale We evaluated the effects of haloperidol and its
metabolites on capsaicin-induced mechanical hypersensi-
tivity (allodynia) and on nociceptive pain induced by
punctate mechanical stimuli in mice.
Results Subcutaneous administration of haloperidol or its
metabolites I or II (reduced haloperidol) dose-dependently
reversed capsaicin-induced (1μg, intraplantar) mechanical
hypersensitivity of the hind paw (stimulated with a non-
painful, 0.5-g force, punctate stimulus). The order of
potency of these drugs to induce antiallodynic effects was
the order of their affinity for brain sigma-1 (σ1) receptor
([
3H](+)-pentazocine-labeled). Antiallodynic activity of
haloperidol and its metabolites was dose-dependently
prevented by the selective σ1 receptor agonist PRE-084,
but not by naloxone. These results suggest the involvement
of σ1 receptors, but discard any role of the endogenous
opioid system, on the antiallodynic effects. Dopamine
receptor antagonism also appears unlikely to be involved
in these effects, since the D2/D3 receptor antagonist
(−)-sulpiride, which had no affinity for σ1 receptors,
showed no antiallodynic effect. None of these drugs
modified hind-paw withdrawal after a painful (4 g force)
punctate mechanical stimulus in noncapsaicin-sensitized
animals. As expected, the control drug gabapentin showed
antiallodynic but not antinociceptive activity, whereas
clonidine exhibited both activities and rofecoxib, used as
negative control, showed neither.
Conclusion These results show that haloperidol and its
metabolites I and II produce antiallodynic but not anti-
nociceptive effects against punctate mechanical stimuli and
suggest that their antiallodynic effect may be due to








Sigma (σ) receptors, initially considered a subtype of
opioid receptors and later confused with phencyclidine
binding sites in N-methyl-D-aspartate (NMDA) receptors,
are now described as a distinct pharmacological entity (for
reviews, see Guitart et al. 2004; Monnet and Maurice
2006). Two subtypes (σ1 and σ2) have been pharmacolog-
ically characterized. The σ1 receptor, cloned in several
animal species and humans, has been described as a unique
protein with no homology with known mammalian proteins
(Guitart et al. 2004; Monnet and Maurice 2006). Drug
binding to σ1 receptors is allosterically modulated by
phenytoin (Quirion et al. 1992), and testing for this
modulation has been proposed as a method to discriminate
between σ1 receptor agonists and antagonists in vitro
(Cobos et al. 2005, 2006). The pharmacology of σ1
receptors is now well-characterized, and selective agonists,
Psychopharmacology (2009) 205:21–33
DOI 10.1007/s00213-009-1513-8
J. M. Entrena: E. J. Cobos: F. R. Nieto:C. M. Cendán:
J. M. Baeyens:E. Del Pozo (*)
Department of Pharmacology and Institute of Neuroscience,
Faculty of Medicine, University of Granada,
Avenida de Madrid 11,
18012 Granada, Spain
e-mail: edpozo@ugr.es
J. M. Entrena: E. J. Cobos
Biomedical Research Center, University of Granada,
Parque Tecnológico de Ciencias de la Salud,
18100 Armilla, Granada, Spainsuch as (+)-pentazocine and PRE-084 [2-(4-morpholinethyl)
1-phenylcyclohexanecarboxylate) hydrochloride], and
antagonists, such as BD-1063 (1-[2-(3,4-dichlorophenyl)
ethyl]-4-methylpiperazine dihydrochloride) and NE-100 (N,
N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl-
amine hydrochloride), are both available (Guitart et al.
2004; Hayashi and Su 2004). Some neurosteroids, psy-
chostimulants, and antipsychotics also bind to σ1 receptors
(Maurice et al. 2001; Monnet and Maurice 2006; Cobos
et al. 2008). Among the antipsychotics, haloperidol (HP) is
mainly known as a D2 receptor antagonist, although it shows
the same affinity for D2 and σ1 receptors (Bowen et al. 1990;
Matsumoto and Pouw 2000) and exhibits σ1 receptor
antagonistic activity (Maurice et al. 2001; Hayashi and Su
2004). Two major metabolic pathways for HP have been
identified in experimental animals and humans (for refer-
ences, see Cobos et al. 2007). One is a reversible reductive
pathway that produces HP metabolite II (HP-Met-II), also
called reduced HP [4-(4-chlorophenyl)-α-(4-fluorophenyl)-
4-hydroxy-1-piperidinebutanol]. The other is an oxidative
N-dealkylation pathway that leads to HP metabolites I
(HP-Met-I, 4-(4-chlorophenyl)-4-hydroxypiperidine) and III
(HP-Met-III, p-fluorobenzoylpropionic acid). Studies
performed in rodent brain membranes and human neuroblas-
toma cells showed that metabolites I and II of HP bind to σ1
receptors with less affinity than HP, but show much lower
(HP-Met-II) or no affinity (metabolite I) for D2 receptors,
whereas metabolite III has no affinity for either σ1 or D2
receptors (Bowen et al. 1990; Matsumoto and Pouw 2000;
Cobos et al. 2007).
Sigma-1 receptors are involved in nociception, among
other processes. They are distributed in the central nervous
system in areas of great importance for pain control, such as
the superficial layers of the spinal cord dorsal horn, the
periaqueductal gray matter, the locus coeruleus, and
rostroventral medulla (Alonso et al. 2000; Kitaichi et al.
2000). Functional studies have postulated that an endoge-
nous σ1 system tonically modulates the opioid system. The
antinociception induced by agonists of opioid receptors in
the tail flick test is antagonized by systemic administration
of the selective σ1 agonist (+)-pentazocine, whereas it is
enhanced by the σ1 antagonist HP (Chien and Pasternak
1993, 1994; Mei and Pasternak 2002, 2007). New σ1
ligands such as the σ1 antagonist (+)-MR 200 [(+)-methyl
(1R,2S)-2-{[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]
methyl}-1-phenylcyclopropanecarboxylate] and the
proposed σ1 agonist (±)-PPCC [(1R,2S/1S,2R)-2-[4-hy
droxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)
cyclopropanecarboxylate] also modulate opioid receptor
agonist-induced antinociception (Marrazzo et al. 2006;
Prezzavento et al. 2008). Sigma ligands are also able to
modulate nociception per se (i.e., not associated to opioid
agonists). Selective σ1 agonists induce nociception when
used alone in the nociceptive flexor response test and the
effects of (+)-pentazocine are reversed by selective σ1
receptor antagonists (Ueda et al. 2001). Moreover, both
phases of pain behavior in the formalin test are diminished
in σ1 receptor knockout mice (Cendán et al. 2005a) and
after the systemic administration of the σ1 receptor
antagonists HP and reduced HP (Cendán et al. 2005b).
Pain behavior in the second phase of the formalin test is also
reduced after intrathecal administration of the σ1 receptor
antagonists BD-1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-
methyl-2-(dimethylamino ethylamine dihydrobromide) and
BMY-14802 (α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-
1-piperazinebutanol) (Kim et al. 2006). However, the
possible role of σ1 receptors in mechanical stimulus-
induced pain is unknown.
The intradermal injection of capsaicin induces an
immediate pain behavior response followed by longer-
lasting secondary mechanical hypersensitivity (Gilchrist
et al. 1996; Joshi et al. 2006). The mechanisms underlying
the mechanical hypersensitivity (allodynia) produced by the
intradermal injection of capsaicin and the second phase of
the formalin test are comparable, involving a phenomenon
of central sensitization produced and maintained mainly by
NMDA receptor stimulation (South et al. 2003; Zou et al.
2000; Soliman et al. 2005). Sigma-1 receptors play an
important modulatory role in NMDA receptor activity
(Debonnel and de Montigny 1996; Kim et al. 2006) and
even modulate acute pain induced by NMDA (Kim et al.
2008). Therefore, we hypothesized that σ1 receptor ligands
might be able to modify the mechanical allodynia induced
by capsaicin.
The main aim of this study was to evaluate the effects of
the sigma ligands HP and its metabolites on mechanical
hypersensitivity induced by the intraplantar injection of
capsaicin and to determine whether these effects are due to
their antagonism of σ1 receptors. To this end, we correlated
the effect of drugs in behavioral tests with their affinity for
brain σ1 receptors labeled with [
3H](+)-pentazocine and
attempted to prevent the effects of HP and its metabolites
by administering the prototype σ1 receptor agonist PRE-084
(Su et al. 1991; Cobos et al. 2008). To control for the
influence of dopaminergic antagonism on the effects of
interest, we evaluated the effect of (−)-sulpiride, a D2 and D3
receptor antagonist devoid of activity on σ1 receptors
(Freedman et al. 1994; Matsumoto and Pouw 2000).
Involvement of endogenous opioid system modulation in
the antiallodynic effect of HP and its metabolites was tested
by evaluating the possible antagonism of this effect by the
opioid receptor antagonist naloxone. We also tested the effect
of HP and its metabolites on pain induced by mechanical
punctate stimuli in animals not sensitized with capsaicin. The
activity of these drugs was compared with that of control
drugs (gabapentin, clonidine, and rofecoxib) with known
22 Psychopharmacology (2009) 205:21–33effects on capsaicin-induced mechanical hypersensitivity or
mechanical pain. Finally, we used the rotarod test to explore




Female CD-1 mice (Charles River, Barcelona, Spain)
weighing 25–30 g were used for all experiments. The animals
were housed in a temperature-controlled room (21±1°C) with
air exchange every 20 min and an automatic 12-h light/dark
cycle (0800 to 2000 hours). They were fed a standard
laboratory diet and tap water ad libitum until the beginning
of the experiments. The experiments were performed during
the light phase (0900–1500 hours). Naive animals were used
throughout the study. Mice were always handled in accor-
dance with the European Communities Council Directive of
24November1986(86/609/ECC). The experimentalprotocol
was approved by the Research Ethics Committee of the
University of Granada, Spain.
Drugs and drug administration
The σ ligands used (and their suppliers) were the nonselective
σ1 antagonists haloperidol (HP), haloperidol metabolite I
[HP-Met-I, 4-(4-chlorophenyl)-4-hydroxypiperidine], halo-
peridol metabolite II [HP-Met-II, 4-(4-chlorophenyl)-α-(4-
fluorophenyl)-4-hydroxy-1-piperidinebutanol], and
haloperidol metabolite III (HP-Met-III, p-fluorobenzoylpro-
pionic acid) (all from Sigma-Aldrich Química S.A., Madrid,
Spain), as well as the selective σ1 antagonist BD-1063
(1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihy-
drochloride) and the selective σ1 agonist PRE-084
[2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate)
hydrochloride] (both from Tocris Cookson, Bristol, UK). As
a control of dopaminergic antagonism, we used the D2 and
D3 antagonist (−)-sulpiride (Sigma-Aldrich Química S.A.,
Madrid, Spain). We also used naloxone hydrochloride
(Sigma-Aldrich Química S.A.) and morphine hydrochloride
(General Directorate of Pharmacy and Drugs, Spanish
MinistryofHealth)toevaluatethe involvementofopioidergic
system modulation in the antiallodynic effect of HP and its
metabolites. Three additional drugs (all from Sigma-Aldrich
Química S.A.) were used as controls in the behavioral assays:
(a) clonidine, which has antinociceptive and antiallodynic
effects (Paqueron et al. 2003); (b) gabapentin, which has
antiallodynic but not antinociceptive effects (Joshi et al.
2006, Tanabe et al. 2005); and (c) rofecoxib, an anti-
inflammatory drug (Moore et al. 2005) ,w h i c hi sd e v o i do f
antinociceptive and antiallodynic activity in animals
without inflammation (Bingham et al. 2005;P a d ia n d
Kulkarni 2004).
The radioligand used for binding assays was [
3H](+)-
pentazocine with a specific activity of 33.6 Ci/mmol
(PerkinElmer Life Sciences, Boston, MA, USA). Dilutions
from the stock [
3H](+)-pentazocine solution were prepared
with ice-cold incubation buffer (50 mM HCl–Tris buffer
pH8 at 30°C). Haloperidol, HP metabolites I, II, III, and
(−)-sulpiride were dissolved in absolute ethanol to make up
a stock solution of 1 mM from which further dilutions were
prepared with incubation buffer to yield a final maximal
concentration of ethanol in the incubation medium of 1%
(v/v). We previously verified that this final concentration of
ethanol did not affect the binding of [
3H](+)-pentazocine.
The other cold drugs (PRE-084, gabapentin, clonidine, and
rofecoxib) used in competition binding assays were
dissolved in deionized ultrapure water.
The drugs were suspended in 5% gum arabic (Sigma-
Aldrich Química S.A.) in water for in vivo assays, and all
were injected subcutaneously (s.c.) into the interscapular
region. An equal volume of vehicle was used in control
animals. When PRE-084 was used to reverse the effects of
HP or its metabolites, it was s.c. injected immediately
before the other drug solution. Each injection was
performed in different areas to avoid mixture of the drug
solutions and any interference with results due to physico-
chemical interaction. The chemical algogen used was
capsaicin (Sigma-Aldrich Química S.A.), which was dis-
solved in 1% dimethyl sulfoxide (DMSO; Merck KGaA,
Darnstadt, Germany) in physiological sterile saline to a
concentration of 0.05µg/µL. Capsaicin solution was
injected intraplantarly (i.pl.) into the right hind paw in a
volume of 20µL, using a 1710 TLL Hamilton microsyringe
(Teknokroma, Barcelona, Spain) with a 30
1/2-gauge needle.
Control animals were injected with the same volume of
capsaicin solvent (DMSO 1% in saline).
Mice brain membrane preparations
Crude synaptosomal membranes (P2 fraction) were prepared
for [
3H](+)-pentazocine binding as previously described
(Cobos et al. 2006) with slight modifications. Mice were
killed by cervical dislocation and the brain was rapidly
removed and homogenized in 15 volumes (w/v) of 0.32 M
sucrose–10 mM Tris–HCl, pH7.4, with a Polytron homog-
enizer (model PT10-35, Kinematica AG, Basel,
Switzerland). The homogenates were centrifuged (Avanti
30, Beckman Coulter España S.A., Madrid, Spain) at
1,000×g for 13 min, the resulting pellets were discarded,
and the supernatants were centrifuged at 21,000×g for
15 min to obtain the P2 pellets; each pellet, obtained from
two whole brains, was resuspended in 15 mL of 10 mM
Tris–HCl, pH7.4, and centrifuged again at 21,000×g for
Psychopharmacology (2009) 205:21–33 2315 min. The entire process was performed at 4°C. Finally,
each pellet was resuspended in 1 mL of 10 mM Tris–HCl,
pH7.4, and frozen in aliquots (protein concentration 12–
14 mg/mL) at −80°C. The binding characteristics of the
tissue were stable for at least 1 month when stored at −80°C.
Protein concentrations were measured by the method of
Lowry et al. (1951) with some modifications, using bovine
serum albumin as the standard.
[
3H](+)-Pentazocine binding assays
To test the affinities of drugs for mice brain σ1 receptors,
we performed [
3H](+)-pentazocine competition binding
assays. Aliquots of mice brain membranes were slowly
thawed and resuspended in fresh incubation buffer and [
3H]
(+)-pentazocine binding assays were performed as previ-
ously described (Cobos et al. 2007) with slight modifica-
tions. Resuspended membrane preparations (460µL) were
incubated at a final protein concentration of 0.8 mg/mL
with 20µL of several concentrations of the cold drug or its
solvent and with 20µL [
3H](+)-pentazocine (final concen-
tration of 5 nM) for 240 min at 30°C, pH8. Nonspecific
binding was defined as the binding retained in the presence
of HP 10µM and was always less than 20% of the total
binding.
To stop [
3H](+)-pentazocine binding to the mouse brain
membranes, 5 mL ice-cold filtration buffer (Tris 10 mM,
pH7.4) was added to the tubes. The bound and free
radioligand were separated by rapid filtration under a
vacuum using a Brandel cell harvester (Model M-12 T,
Brandel Instruments, SEMAT Technical, St. Albans,
Hertfordshire, UK) over Whatman GF/B glass fiber filters
(SEMAT Technical, St. Albans, Hertfordshire, UK) pre-
soaked with 0.5% polyethylenimine in Tris 10 mM, pH7.4,
for at least 1 h prior to use, to reduce nonspecific binding.
The filters were washed under a vacuum twice with 5-mL
volumes of the ice-cold filtration buffer and transferred to
scintillation counting vials. Then, 4 mL liquid scintillation
cocktail (CytoScint scintillation counting solution, MP
Biomedicals, Irvine, CA, USA) was added to each vial
and the mixture was equilibrated for at least 20 h. The
radioactivity retained in the filter was measured with a
liquid scintillation spectrometer (Beckman Coulter España
S.A.) with an efficiency of 52%. Each assay was conducted
in triplicate.
Evaluation of mechanical punctate nociceptive pain
and capsaicin-induced mechanical hypersensitivity
Animals were placed in the experimental room (under low
illumination) to allow them to acclimatize to the study room
for 1 h before the experiments were begun. After that time,
the animals were placed into individual test compartments
for 2 h before the test to habituate them to the test
conditions. The test compartments had black walls and
were situated on an elevated mesh-bottomed platform with
a 0.5-cm
2 grid to provide access to the ventral surface of the
hind paws. After this period, the animals were carefully
removed from the compartment, injected i.pl. with 1µg
capsaicin (or its solvent) in the right hind paw proximate to
the heel, and immediately returned to the compartment. In
all experiments, punctate mechanical stimulation was
applied with a Dynamic Plantar Aesthesiometer (Ugo
Basile, Varese, Italy) at 15 min after the administration of
capsaicin (time to maximum effect, data not shown) or its
solvent. Briefly, a nonflexible filament (0.5 mm diameter)
was electronically driven into the ventral side of the paw
previously injected with capsaicin or solvent (i.e., the right
hind paw), at least 5 mm away from the site of the injection
towards the fingers. When a paw withdrawal response
occurred, the stimulus was automatically terminated and the
response latency time was automatically recorded. A cut-off
time of 50 s was used. In all experiments, the filament was
applied to the right hind paw of each mouse three times,
separated by intervals of 0.5 min, and the mean value of the
three trials was considered the withdrawal latency time of
the animal.
Responses to mechanical stimuli were compared between
control (DMSO-treated) and capsaicin-sensitized mice by
applying the filament at a wide range of electronically
controlled intensities from 0.05 to 8 g force, recording the
paw withdrawal latency time for each force applied as
described above. Each animal was tested using only one
intensity of mechanical stimulation in order to maintain a
strictly constant time (15 min) between administration of
capsaicin or its solvent and the behavioral evaluation. As
expected, shorter withdrawal latency times were obtained as
higher forces were applied (see Fig. 2 and the “Results”
section). This approach allowed us to construct a force–
response curve (i.e., intensity of the stimulus versus paw
withdrawal latency time) and to quantify the degree of
mechanical punctate nociceptive pain in DMSO-treated
animals and the mechanical sensitization in capsaicin-
treated animals.
When the effects of drugs were tested, the drug under
study (or its solvent) was administered s.c. 30 min before
the i.pl. administration of capsaicin or DMSO 1% (i.e.,
45 min before we evaluated the response to the mechanical
punctate stimulus). The antinociceptive effects of drugs
were assessed in DMSO-treated animals using a mechanical
stimulation of 4 g force, which induced a marked reduction
in paw withdrawal latency time in these nonsensitized mice
(for details, see Fig. 2 and the “Results” section). The
antiallodynic effects of the drugs were evaluated in
capsaicin-sensitized mice using a mechanical stimulation
of 0.5 g force. This intensity of the mechanical stimulus did
24 Psychopharmacology (2009) 205:21–33not induce paw withdrawal in DMSO-treated mice, but
markedly reduced paw withdrawal latency time in
capsaicin-sensitized mice. We chose these forces because
the latency time in capsaicin-sensitized animals stimulated
with 0.5 g was similar to that in nonsensitized animals
(DMSO-treated) stimulated at 4 g force (see Figs. 2 and 6).
Rotarod test
Changes in motor coordination were tested with an acceler-
ating rotarod (Cibertec, Madrid, Spain) as previously
described (Nieto et al. 2008) with slight modifications.
Briefly, mice were required to walk against the motion of
an elevated rotating drum at speeds increasing from 4 to
40 rpm over a 300-s period. The latency to fall down was
recorded automatically with a cut-off time of 300 s. Twenty-
four hours prior to each experiment with drugs, mice were
acclimatized to the apparatus in three training sessions on the
rotarod separated by 30-min intervals. On the day of the test,
rotarod latencies were measured immediately before (time 0)
and 45 min after the drug or vehicle was given. This time
was chosen because it was the time used to test the effects of
drugs on mechanical hypersensitivity.
Data analysis
We estimated the concentration of unlabeled drug that inhibited
50% of [
3H](+)-pentazocine specific binding (IC50) values and
their standard errors from the inhibition curves with nonlinear
regression analysis of the equation for a sigmoid plot,
assuming one-site competition; the SigmaPlot v. 8.0 (2002)
program was used for all estimates. The force of mechanical
stimulus applied that produced half the maximal reduction in
paw withdrawal latency time (EF50) values were calculated
from the force–response curves using nonlinear regression
analysis of the equation for a sigmoid plot. The degree of
effect on capsaicin-induced mechanical hypersensitivity
was calculated as: %reductionmechanicalhypersensitivity ¼
LTD   LTS ðÞ = CT   LTS ðÞ ½    100 where LTD is the
latency time for paw withdrawal in drug-treated animals, LTS
isthelatencytimeinsolvent-treatedanimals,andCTisthecut-
off time (50 s). The dose of drug that produced half the
maximal inhibition of mechanical allodynia (ED50) and
maximum antiallodynic effect (Emax) values were calculated
from the dose–response curves using nonlinear regression
analysis of the equation for a sigmoid plot. The EF50,E D 50,
and Emax values obtained from sigmoid plots and their
standard errors were calculated as the best-fit values±standard
errors of regression with the SigmaPlot v. 8.0 (2002)
program.
The values obtained in several experimental groups were
compared with one-way or two-way analysis of variance
(ANOVA) followed by the Bonferroni test. Differences
between two means were assessed by the Student’s t test.
The differences were considered significant when the value
of P was below 0.05.
Results
Affinity of drugs for [
3H](+)-pentazocine binding sites
in the mouse brain
We used competition binding assays to test the affinities of
the drugs under study for the σ1 receptor, labeled with [
3H]
(+)-pentazocine, in mouse brain membranes (P2 fraction).
Specific binding of [
3H](+)-pentazocine (which always
represented more than 80% of the total binding) was
concentration-dependently inhibited by the unlabeled
ligands with the following order of potency (IC50 values):
HP (5.45±0.48 nM)>HP-Met-II (12.80±0.69 nM)>PRE-
084 (171.40±18.36 nM)>HP-Met-I (254.18±18.40 nM)
>>>HP-Met-III or (−)-sulpiride (the last two compounds
had negligible affinity for [
3H](+)-pentazocine binding
sites, with IC50>10,000 nM) (Fig. 1 and Table 1). The
drugs used as controls in the behavioral tests (gabapentin,
clonidine, and rofecoxib) also did not substantially decrease
[
3H](+)-pentazocine binding, showing IC50 values higher
than 10,000 nM (data not shown).
Fig. 1 Inhibition by unlabeled drugs of [
3H](+)-pentazocine specific
binding to membranes (P2 fraction) obtained from whole mouse brain.
[
3H](+)-pentazocine (5 nM) was incubated with 0.8 mg/mL brain
membrane protein at 30°C, pH8, for 240 min and increasing
concentrations of haloperidol (HP, filled circles), haloperidol metabo-
lite I (HP-Met-I, filled squares), haloperidol metabolite II (HP-Met-II,
filled triangles), haloperidol metabolite III (HP-Met-III, filled inverted
triangles), PRE-084 (open squares), or (−)-sulpiride (filled diamonds).
Data shown are the average of two experiments carried out in
triplicate
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and capsaicin-induced mechanical hypersensitivity
We applied the filament at different intensities ranging from
innocuous to noxious stimuli (0.05–8 g force) in mice
treated with capsaicin (1µg, i.pl.) or its solvent. As
expected, paw withdrawal latency time decreased as the
force applied increased in both experimental situations
(Fig. 2). Forces higher than 1 g were needed to induce paw
withdrawal in nonsensitized (DMSO-treated) mice, and the
shortest withdrawal latency time was obtained at 8 g force
(Fig. 2). In contrast, a weak mechanical stimulus (0.2 g)
was sufficient to induce paw withdrawal in capsaicin-
sensitized mice, and withdrawal latency time was minimal
at forces as low as 0.5–1 g (Fig. 2). Treatment with
capsaicin produced a 9.4-fold decrease in the EF50 value for
inducing paw withdrawal in comparison to control mice
(EF50 values of 2.59±0.08 and 0.30±0.02 g for DMSO-
treated and capsaicin-treated animals, respectively), which
clearly indicates that capsaicin induced mechanical hyper-
sensitivity to punctate stimuli.
Effect of haloperidol and its metabolites on capsaicin-induced
mechanical hypersensitivity
The effects of s.c. administration of drugs was investigated as
the change in mechanical hypersensitivity induced by intra-
plantar capsaicin. Injection of the σ1 ligands HP (0.004–
0.25 mg/kg), HP-Met-II (0.04–2 mg/kg), and HP-Met-I (8–
128 mg/kg) induced a dose-dependent increase in withdrawal
latency in the capsaicin-injected hind paw when stimulated
with a filament at 0.5 g force, i.e., they produced antiallodynic
effects (Fig. 3). The order of potency in these effects (ED50
values) was: HP (0.026±0.006 mg/kg)>HP-Met-II (0.135±
0.03 mg/kg)>>HP-Met-I (31.05±7.83 mg/kg), the same as
the order of potency of these compounds for displacing [
3H]
(+)-pentazocine binding in mouse brain membranes (Table 1).
The maximum effect (Emax) for each drug was calculated
by regression analysis. Haloperidol and its metabolite II
produced the maximum possible effect in this model (Emax=
100%); however, the Emax f o rH P - M e t - Iw a sl o w e r( 6 2 . 2 7 ±
6.99%).
Interestingly, HP-Met-III and (−)-sulpiride, which had no
affinity for [
3H](+)-pentazocine-labeled σ1 receptor (Fig. 1;
Table 1), showed no antiallodynic effects even at very high
doses (128 and 100 mg/kg, s.c., respectively) (Fig. 3 and
Table 1).
Table 1 Potencies of several drugs in inhibiting the specific binding of [
3H](+)-pentazocine to mouse brain membranes and the mechanical
hypersensitivity (allodynia) induced by intraplantar capsaicin in mice
Drug IC50 (nM) ED50 (mg/kg, s.c)
Sigma-1 antagonists Haloperidol 5.45±0.48 0.026±0.006
Haloperidol metabolite II 12.80±0.69 0.135±0.03
Haloperidol metabolite I 254.18±18.40 31.05±7.83
Sigma-1 agonist PRE-084 171.40±18.36 Inactive
a




The IC50 values (concentration of unlabeled drug that inhibited the specific binding of [
3H](+)-pentazocine by 50%) were obtained with
competition assays performed in mouse brain membranes (P2 fraction). The ED50 values (dose of drug producing half of the maximal
antiallodynic effect) were obtained from dose–response curves of the drug’s effects on withdrawal response latency time of the capsaicin-
sensitized paw after stimulation with a punctate mechanical stimulus at 0.5 g force. See the “Materials and methods” section for details
aThe effect of PRE-084 was tested at 32–64 mg/kg, s.c. The dose of haloperidol metabolite III was 128 mg/kg, s.c., and the dose of (−)-sulpiride
was 100 mg/kg, s.c.
Fig. 2 Withdrawal latency time of the hind paw stimulated with a
filament at different forces, 15 min after the intraplantar injection of
capsaicin (1μg, filled circles) or its solvent (DMSO 1%, open circles).
Each point and vertical line represent the mean±SEM of the values
obtained in an independent group of animals (n=6–8 per group). Each
group was tested with only one stimulation force. Statistically
significant differences between the latency time values obtained with
each applied force under the two experimental conditions: **P<0.01
(two-way ANOVA followed by Bonferroni test)
26 Psychopharmacology (2009) 205:21–33Reversion of the antiallodynic effects of haloperidol
and its metabolites by the selective σ1 receptor agonist
PRE-084
The known σ1 receptor agonist PRE-084 did not modify
paw withdrawal latency in capsaicin-treated animals at
either dose (32 or 64 mg/kg s.c.) (Fig. 4 and Table 1).
However, PRE-084 (16–64 mg/kg, s.c.) produced a dose-
dependent reversion of the antiallodynic effect of HP
(0.06 mg/kg, s.c.) (Fig. 4). The highest dose of PRE-084
abolished the effect of HP, and paw withdrawal latency
was similar to that in animals treated with the drug
solvent (Fig. 4). PRE-084 (32–64 mg/kg, s.c.) also
completely and dose-dependently prevented the antiallo-
dynic effects of HP-Met-II (0.25 mg/kg, s.c.) and HP-Met-I
(64 mg/kg, s.c.) (Fig. 4). As a control, we evaluated the
ability of PRE-084 to reverse the effect of BD-1063, a
selective antagonist of σ1 receptors (Matsumoto et al.
1995; Hayashi and Su 2004). We found that BD-1063
(20 mg/kg, s.c.) produced an increase in paw withdrawal
latency similar to that induced by HP and its metabolites I
and II and that the antiallodynic effect of BD-1063 was
completely antagonized by PRE-084 (32 mg/kg, s.c.)
(Fig. 4).
Effect of naloxone on the antiallodynic activity of morphine,
haloperidol, and its metabolites
As expected, morphine (0.25 mg/kg, s.c.) inhibited
mechanical hypersensitivity induced by capsaicin, and
its effect was reversed by the opioid receptor antagonist
naloxone (1 mg/kg, s.c.) (Fig. 5). In contrast, the same
dose of naloxone did not significantly modify the
antiallodynic effect of HP (0.06 mg/kg, s.c.), HP-Met-II
(0.25 mg/kg, s.c.), or HP-Met-I (64 mg/kg, s.c.) (Fig. 5).
Fig. 4 Effects of the association of subcutaneous administration of
PRE-084 (16-64 mg/kg) or its solvent with haloperidol (HP, 0.06 mg/
kg), haloperidol metabolite II (HP-Met-II, 0.25 mg/kg), haloperidol
metabolite I (HP-Met-I, 64 mg/kg), BD-1063 (20 mg/kg), or their
solvent (all injected s.c.) on mechanical hypersensitivity induced by
the intraplantar injection of capsaicin (1µg) to the mouse hind paw.
The results represent the latency to hind-paw withdrawal of the
capsaicin-sensitized paw after ipsilateral stimulation with a filament at
0.5 g force (see the “Materials and methods” section for details). Each
bar and vertical line represent the mean±SEM of the values obtained
in an independent group of animals (n=8–10 per group). Each group
was treated with only one of the drugs (or their solvent) associated to
one dose of PRE-084 or its solvent. Statistically significant differences
between the values obtained in each drug-treated group with respect to
the solvent-treated group: *P<0.05; **P<0.01. Statistically signifi-
cant differences between the values obtained in the groups treated with
each drug (HP, HP-Met-II, HP-Met-I, or BD-1063) associated with
PRE-084 with respect to those in the groups treated with each drug
associated with PRE-084 solvent: ##P<0.01 (two-way ANOVA
followed by Bonferroni test)
Fig. 3 Effects of different doses of subcutaneously administered
haloperidol (HP, filled circles), haloperidol metabolite II (HP-Met-II,
filled triangles), haloperidol metabolite I (HP-Met-I, filled squares),
haloperidol metabolite III (HP-Met-III, filled inverted triangles),
(−)-sulpiride (filled diamonds), or their vehicle (open diamonds)o n
mechanical hypersensitivity (allodynia) induced by intraplantar injec-
tion of capsaicin (1µg) to mouse hind paw. The results represent the
percentage reduction in capsaicin-induced mechanical hypersensitivity
(calculated as explained in the “Materials and methods” section). Each
point and vertical line represent the mean±SEM of the values obtained
in an independent group of animals (n=8–10 per group). Each group
was treated with only one dose of drug or solvent. Statistically
significant differences between the values obtained in solvent-injected
and drug-injected groups: **P<0.01 (one-way ANOVA followed by
Bonferroni test)
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of haloperidol, its metabolites, and control drugs
To compare the effects of drugs on mechanical punctate
stimuli-induced nociceptive pain (in nonsensitized animals)
and mechanical allodynia (in capsaicin-treated animals), we
chose mechanical intensity stimuli that produced similar
withdrawal latency times in both experimental situations.
Thus, when animals were pretreated with drug solvent, the
withdrawal latency time obtained after stimulation with a 4-g
force in nonsensitized (1% DMSO-treated) mice (6.58±
1.17 s) was very similar to that obtained in animals treated
withcapsaicin(1µg,i.pl.)andstimulatedat0.5gforce(8.03±
0.84 s; Fig. 6).
The subcutaneous administration of HP, HP-Met-II, or
HP-Met-I (0.125, 0.5, or 64 mg/kg, respectively) markedly
increased paw withdrawal latency time in capsaicin-
sensitized animals stimulated with the filament at 0.5 g
force. Therefore, they exerted antiallodynic effects, which
were maximal for HP and HP-Met-II (Fig. 6, left panel).
The control drugs gabapentin (64 mg/kg, s.c.) and clonidine
(0.5 mg/kg, s.c.) also induced a marked antiallodynic effect
in capsaicin-treated animals (Fig. 6, left panel). However,
as expected, rofecoxib was inactive in this behavioral test
(Fig. 6, left panel).
Nonsensitized (DMSO-treated) mice treated with the σ1
receptor antagonists HP, HP-Met-I, and HP-Met-II (at the
same doses that showed maximal antiallodynic effects) did
not increase paw withdrawal latencies after stimulation
with a filament at 4 g force, i.e., these drugs did not exert
any antinociceptive effect on punctate mechanical noci-
ceptive pain (Fig. 6, right panel). Gabapentin and
rofecoxib were also devoid of effect against this noxious
punctate mechanical stimulus (Fig. 6, right panel).
However, clonidine (0.5 mg/kg, s.c.) increased the paw
withdrawal latency time up to the cut-off time in non-
sensitized mice stimulated with the filament at 4 g force
(Fig. 6, right panel), inducing a clear antinociceptive
effect.
Effect of drugs on the rotarod test
The latency to fall down from the rotarod before the drug or
solvent was injected (time 0) was similar in all experimental
groups (data not shown). The s.c. administration of HP
(0.06 mg/kg), HP-Met-I (64 mg/kg), and HP-Met-II
(0.25 mg/kg) had no effect on rotarod latency in comparison
to control (solvent-treated) animals 45 min after administra-
tion (Fig. 7a), i.e., they did not interfere with motor
coordination at times and doses that produced around 70%
of the maximum antiallodynic effect (compare Figs. 4 and
7a). The s.c. administration of (−)-sulpiride (100 mg/kg),
HP-Met-III (128 mg/kg), or PRE-084 (64 mg/kg) was also
devoid of any effect on rotarod latency (Fig. 7a, b).
On the other hand, animals treated with higher doses of
HP (0.125 mg/kg, s.c.) or HP-Met-II (1 mg/kg, s.c.), which
produced 100% of the antiallodynic effect (see Fig. 3),
showed a significant decrease in rotarod latencies in
comparison to both their own values at time 0 (data not
shown) and the values in solvent-treated animals at 45 min
after administration (Fig. 7b). Interestingly, the effects of
HP and HP-Met-II in the rotarod test were not prevented by
PRE-084 at a dose (64 mg/kg, s.c.) that completely
prevented the antiallodynic effect of both drugs (compare
Figs. 4 and 7b).
Discussion
The main findings of this study were that the subcutaneous
administration of HP or HP metabolites I or II dose-
dependently antagonized capsaicin-induced mechanical
allodynia (probably by blocking σ1 receptors) but did not
modify nociceptive pain induced by a painful punctate
stimulus in nonsensitized animals. These effects have not
been previously reported.
Fig. 5 Effects of the association of subcutaneous administration of
naloxone (1 mg/kg) or its solvent with morphine (0.25 mg/kg),
haloperidol (HP, 0.06 mg/kg), haloperidol metabolite II (HP-Met-II,
0.25 mg/kg), and haloperidol metabolite I (HP-Met-I, 64 mg/kg) on
mechanical hypersensitivity induced by the intraplantar injection of
capsaicin (1µg) to the mouse hind paw. The results represent the
latency to hind-paw withdrawal of the capsaicin-sensitized paw after
ipsilateral stimulation with a filament at 0.5 g force (see the “Materials
and methods” section for details). Each bar and vertical line represent
the mean±SEM of the values obtained in an independent group of
animals (n=8–10 per group). Each group was treated with only one of
the drugs under study associated to naloxone or its solvent. Statistically
significant differences in values were only found between the
morphine-treated and morphine+naloxone-treated groups: **P<0.01
(nonpaired Student's t test)
28 Psychopharmacology (2009) 205:21–33We found that the intraplantar injection of capsaicin
produced mechanical allodynia (sensitization to an innoc-
uous mechanical punctate stimulus), which was manifested
by both a decrease in the force necessary to induce hind-
paw withdrawal and a decrease in the latency time for paw
withdrawal when a determined force was applied. These
results agree with those of previous studies that also
reported capsaicin-induced mechanical hypersensitivity to
punctate stimulus in rodents (Gilchrist et al. 1996; Joshi
et al. 2006; Brenchat et al. 2009). Under our experimental
conditions, HP, HP-Met-I, and HP-Met-II exerted dose-
dependent antiallodynic effects. It is noteworthy that the
antiallodynic effect of HP is produced at a range of doses
similar to those producing positive effects in animal models
predictive of antipsychotic activity (Natesan et al. 2008;
Millan et al. 2008). The control drugs gabapentin and
clonidine were able to inhibit capsaicin-induced mechanical
allodynia, whereas rofecoxib was inactive. These results
agree with those previously described for gabapentin and
clonidine, both of which exerted antiallodynic effects (Joshi
et al. 2006; Paqueron et al. 2003), and with the lack of
effect of rofecoxib against capsaicin-induced mechanical
hypersensitivity (Bingham et al. 2005).
We also evaluated the effects of the drugs on the
response to mechanical stimuli in nonsensitized (DMSO-
treated) animals. The punctate stimulus at 4 g force is
painful in nonsensitized animals, since it exceeds the
threshold for activation of Aδ- and C-nociceptors in mouse
glabrous skin (Cain et al. 2001)a n di n d u c e sp a w
withdrawal. We chose this force (4 g) in nonsensitized
animals because it produced a paw withdrawal latency
s i m i l a rt ot h a tf o u n di nc a p s a icin-sensitized animals
stimulated with an innocuous force (0.5 g) and allowed us
to evaluate the effect of drugs on nociceptive pain induced
by a type of stimulus qualitatively similar to that used in
capsaicin-sensitized animals. Haloperidol and its metabo-
lites did not affect the response to punctate stimuli in
nonsensitized animals, which suggests that the drugs tested
Fig. 6 Effects of s.c. administration of haloperidol (HP, 0.125 mg/kg),
haloperidol metabolite II (HP-Met-II, 0.5 mg/kg), haloperidol metabolite
I (HP-Met-I, 64 mg/kg), clonidine (0.5 mg/kg), gabapentin (64 mg/kg),
rofecoxib (32 mg/kg), or their solvent on latency time to paw withdrawal
under two experimental conditions: capsaicin-treated paw stimulated at
0.5gforce,i.e.,mechanicalallodynia(left panel), and 1% DMSO-treated
paw stimulated at 4 g force, i.e., mechanical nociceptive pain (right
panel)( s e et h e“Materials and methods” section for details). Each
bar and vertical line represent the mean±SEM of the values obtained
in an independent group of animals (n=8–10 per group). Each group
was treated with only one of the drugs (or their solvent) and tested
under only one of the two experimental conditions. Statistically
significant differences between the values obtained in the drug-
treated and solvent-treated group under the same experimental
conditions: **P<0.01; statistically significant differences between
the effects of each drug tested under the two experimental conditions
(0.5 g force in capsaicin-treated mice versus 4 g force in DMSO-
treated mice):
##P<0.01 (two-way ANOVA followed by Bonferroni
test)
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mechanisms necessary to produce paw withdrawal. Previ-
ous studies have also found that HP and its metabolites did
not modify heat-induced nociceptive pain (tail flick test)
(Chien and Pasternak 1994; Cendán et al. 2005b), but data
on their effect on mechanical nociceptive pain have not
been previously reported. Regarding the drugs used as
controls, our results fully agree with those previously
reported, since neither gabapentin nor rofecoxib affected
mechanical nociception in nonsensitized animals (Tanabe et
al. 2005; Padi and Kulkarni 2004), whereas clonidine
reduced mechanical pain in these animals (Honda et al.
2002; Paqueron et al. 2003).
Haloperidol and HP-Met-II showed affinity for σ1
receptors at nanomolar concentrations (Cobos et al. 2007;
this study) and for D2 and D3 receptors at nanomolar (HP)
and low micromolar (HP-Met-II) concentrations (Bowen
et al. 1990; Jaen et al. 1993). Therefore, their antiallodynic
activity might be due to their effects on σ1 or dopamine
receptors or on both. Interestingly, (−)-sulpiride, which
shows nanomolar affinity for D2 and D3 receptors but no
affinity for σ1 receptors (Freedman et al. 1994; Matsumoto
and Pouw 2000; this study), is devoid of antiallodynic
effects, whereas HP-Met-I, which has affinity for σ1
receptors but not for D2 receptors (Bowen et al. 1990;
Cobos et al. 2007), shows antiallodynic activity. Therefore,
dopamine receptor antagonism seems unlikely to be
involved in the antiallodynic effects of HP and its
metabolites. Because HP also has nanomolar affinity for
α1-adrenoceptors (Millan et al. 2000), these receptors could
play a role in its antiallodynic effect. However, the highly
selective agonist of σ1 receptors PRE-084 has no affinity
for α1-adrenoceptors and many other receptors (Su et al.
1991) but totally inhibits the antiallodynic effects of HP and
its metabolites. This strongly suggests that α1-adrenoceptors
are not involved in their antiallodynic effects.
In contrast, there are several arguments indicating that the
antiallodynic effects of HP and its metabolites are due to
their activity on σ1 receptors. Firstly, their order of potency
for inducing antiallodynic effects correlates with their order
of affinity for σ1 binding sites in mouse brain (this study),
rat brain (Bowen et al. 1990; Matsumoto and Pouw 2000),
guinea pig brain, and human neuroblastoma cells (Cobos et
al. 2007). Secondly, HP-Met-III and (−)-sulpiride, which
Fig. 7 Rotarod latency times obtained 45 min after s.c. administration
of drugs or their solvent. a Effects of the solvent, haloperidol (HP,
0.06 mg/kg), haloperidol metabolite I (HP-Met-I, 64 mg/kg),
haloperidol metabolite II (HP-Met-II, 0.25 mg/kg), haloperidol
metabolite III (HP-Met-III, 128 mg/kg), or (−)-sulpiride (100 mg/
kg). Each bar and vertical line represent the mean±SEM of the values
obtained in an independent group of animals (n=8 per group). Each
group was treated with only one of the drugs (or their solvent) under
study. There were no statistically significant differences between the
values obtained in solvent-treated and drug-treated groups (one-way
ANOVA). b Effects of solvent, PRE-084 (64 mg/kg), and haloperidol
(HP, 0.125 mg/kg), or haloperidol metabolite II (HP-Met-II, 1 mg/kg),
both alone or associated with PRE-084 (64 mg/kg). Each bar and
vertical line represent the mean±SEM of the values obtained in an
independent group of animals (n=8 per group). Each group was
treated with only one of the associations of drugs (or their solvent)
with PRE-084 (or its solvent). Statistically significant differences
between the values obtained in the drug-treated and solvent-treated
groups: *P<0.05; **P<0.01. Statistically significant differences with
respect to the group treated with PRE-084 alone:
##P<0.01. NS
nonsignificant differences (two-way ANOVA followed by Bonferroni
test)
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studies (Bowen et al. 1990; Cobos et al. 2007; Matsumoto
and Pouw 2000), exerted no antiallodynic activity in this
model. Thirdly, the selective σ1 receptor agonist PRE-084
(Su et al. 1991; Hayashi and Su 2004), at doses that do not
produce any effect per se on capsaicin-induced mechanical
sensitization, reversed the antiallodynic effects of HP,
HP-Met I, and HP-Met II. Fourthly, the selective σ1
receptor antagonist BD-1063 (Matsumoto et al. 1995;
Hayashi and Su 2004) produced a response pattern very
similar to that of HP and its metabolites, i.e., an
antiallodynic effect that was fully reversed by the σ1
receptor agonist PRE-084. Therefore, the antiallodynic
effects of the drugs studied seem to be due to their
antagonistic activity on σ1 receptors.
Haloperidol and other σ1 receptor antagonists increase
opioid receptor agonist-induced antinociception (see the
“Introduction” for references). Hence, their ability to inhibit
capsaicin-induced mechanical hypersensitivity might be
due to an increase in the effects of endogenous opioids.
We found that a dose of naloxone that reversed the
antiallodynic effect of morphine was unable to modify the
antiallodynic effects of HP and its metabolites. These
experiments rule out any influence on our results of
modulation of the endogenous opioid system by HP or its
metabolites.
Previous studies have reported that HP and its metabo-
lites I and II, as well as other antagonists of σ1 receptors
such as BD-1047 and BMY-14802, inhibited the second
phase of formalin-induced pain (Cendán et al. 2005b; Kim
et al. 2006). The mechanisms underlying the second phase
of the formalin test and the mechanical hypersensitivity
induced by capsaicin involve a process of central sensiti-
zation in which the activity of glutamatergic NMDA
receptors plays a pivotal role (see Baron 2000 and the
“Introduction” for references). Therefore, either a direct
effect on NMDA receptors or an indirect modulation of
NMDA-mediated effects could explain our results. Halo-
peridol and reduced HP show affinity for NMDA receptors,
but their affinity for NMDA receptors is very low (Ki in the
micromolar range) (Whittemore et al. 1997; Coughenour
and Cordon 1997) in comparison to their affinity for σ1
receptors, which is 1,000 times higher (in the nanomolar
range) (Matsumoto and Pouw 2000; Cobos et al. 2007;
present study). Therefore, a direct effect of HP or its
metabolites on NMDA receptors might be ruled out as an
explanation for their antiallodynic effect in the present
study. On the other hand, it has been reported that σ1
receptor agonists facilitated several NMDA receptor-
mediated electrophysiological effects and that HP and other
σ1 receptor antagonists inhibited these effects of σ1 receptor
agonists (Debonnel and de Montigny 1996; Chen et al.
2006; Martina et al. 2007). Interestingly, low doses of HP
(0.01–0.1 mg/kg), within the range of doses used in the
present study, antagonized the potentiation induced by σ1
receptor agonists of NMDA-mediated response in vivo
(Monnet et al. 1992; Maurice and Privat 1997; Bermack
and Debonnel 2005). Therefore, the antiallodynic effects of
HP and its metabolites might be explained by their ability
to indirectly modulate NMDA-mediated effects through an
action on σ1 receptors.
Unspecific interference on motor coordination does not
appear to explain the antiallodynic effects because doses of
HP, HP-Met-I, and HP-Met-II that lacked activity in the
rotarod test exerted around 70% of the maximum anti-
allodynic activity. Higher doses of HP and HP-Met-II (that
produced 100% of the antiallodynic effect) affected the
response in the rotarod test, but these motor effects were
not reversed by PRE-084 (i.e., were not due to antagonism
of σ1 receptors), whereas PRE-084 reversed the antiallo-
dynic effects. Moreover, neither HP nor HP-Met-II affected
paw withdrawal latency in nonsensitized animals (stimulated
at a force of 4 g) at doses that interfered with rotarod test
responses. Taken together, these results indicate dissocia-
tion between the motor and neurochemical mechanisms
involved in the effects of HP and its metabolites in paw
withdrawal induced by mechanical stimulation and the
rotarod tests.
It is known that σ1 receptor agonists and antagonists
modulate pain processing, acting at both spinal (Kim et al.
2006, 2008) and supraspinal sites (Chien and Pasternak
1994; Mei and Pasternak 2002, 2007; Marrazzo et al.
2006). Therefore, HP and its metabolites might act at any of
these sites to produce their antiallodynic effects. Since we
administered the drugs subcutaneously, our data do not
shed light on the level of central pain processing (spinal or
supraspinal) at which HP and its metabolites produce their
antiallodynic effects, and new experiments will be needed
to identify their level of action.
Regarding the therapeutic potential of our findings, it has
been reported that HP (2–5 mg) is useful in humans to treat
migraine (Honkaniemi et al. 2006), chronic pain (Raft et al.
1979), and reduce nalbuphine-induced hyperalgesia (Gear
et al. 2006). Moreover, a case report described complete
acute relief of neuropathic pain with a 2-mg dose of HP
(Shir et al. 1990). The affinity of HP for σ1 receptors is
high enough to bind to them in humans at therapeutic
doses. In fact, a dose of 3 mg HP occupied around 80% of
σ1 receptors in different areas of the human brain (Ishiwata
et al. 2006). Interestingly, this dose of HP occupies more σ1
than D2 receptors in the human brain (Ishiwata et al. 2006).
This raises the possibility that the analgesic effects
observed with HP in humans might be related to its ability
to bind to σ1 receptors and that the antiallodynic activity of
this compound may have clinical applications. New studies
are necessary to test these possibilities.
Psychopharmacology (2009) 205:21–33 31In summary, our results show that haloperidol and its
metabolites I and II inhibit capsaicin-induced mechanical
hypersensitivity and suggest that the antagonism of σ1
receptors produced by these drugs is responsible for their
antiallodynic effects in this model. These findings raise the
possibility of new therapeutic applications for this antipsy-
chotic drug, which is routinely used for other indications in
humans.
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